Singapore-listed iX Biopharma bets big on non-opioid pain relief
Its flagship drug Wafermine is a sublingual ketamine wafer that delivers rapid pain relief without addiction risks
Add BT as a preferred source
[SINGAPORE] It took semaglutide (an anti-diabetic prescription drug that is gaining traction as an anti-obesity medication) to convince Wall Street that an overlooked drug class could become a hundred-billion-dollar market. Now, a handful of companies are betting that non-opioid pain relief is next – and Singapore’s iX Biopharma thinks it has the edge.
The company’s flagship drug, Wafermine, is a sublingual ketamine wafer designed to dissolve under the tongue and deliver rapid pain relief without the addiction risks that have made opioids so controversial.
Since its listing on the Singapore Exchange (SGX) in 2015, iX Biopharma has been developing Wafermine through the clinical trial process required for regulatory approval.
TRENDING NOW
Singapore private housing is ‘decoupling’ from HDB market as buyer pools diverge: NUS survey
Simba’s 5G spectrum hurdle may accelerate Singapore’s telco market reset
Yen hits 40-year low in historic slide that’s rattled Japan
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
